The beginning of a new year marks the start of a new journey. With the passage of 2020 and the arrival of 2021, Hansoh Pharma extends its most sincere holiday wishes to the hard-working employees and their families, and to the leaders, partners and friends from all walks of life who have long cared about and supported Hansoh Pharma's development.

2021 is the beginning of the sixth Five-Year Plan period (2021-2025)  and also a key stage of transformation and upgrading of Hansoh Pharma. Over the past years, we have built up strong momentum and opened up a good situation for the company's more dynamic and higher quality development. In 2020, faced with the complicated and changeable industry situation, we have remained true to our original aspiration, have always put people's health in the first place, and have forged ahead with perseverance to light up the hope of life with scientific and technological innovation.   

Innovation as the top priority - We have developed a richer and more diversified product portfolio, launched the fourth national Class 1 new drug Ameile, and obtained approval of the first biological drug for clinical use;

Benefiting people's livelihood - Our three innovative drugs have been included into the national reimbursement drug list, improving the accessibility of innovative drugs and effectively benefiting patients;

Lean and intelligent manufacturing: We have strictly observed product quality standards, passed the consistency evaluation of five injection varieties, and obtained approval for marketing of two preparation varieties from the U.S. FDA;

Two-way drive - We have placed equal focus on "bringing in" and "going out", and have taken a global perspective to obtain the first innovative drug license overseas and accelerate higher-level global innovation;

Responsibility - We have won a number of awards in scientific and technological innovation, green and intelligent manufacturing, and corporate social responsibility, and have received wide recognition inside and outside the industry.

The year 2020 marks the 25th anniversary of Hansoh Pharma's establishment. In the past 25 years, we have adhered to the innovation-driven development strategy, built up strong momentum, and achieved the transformation and upgrading from "Made in China" to "Created in China"; in the past 25 years, we have adhered to the patient-centered and quality-based approach, strengthened the research and development of innovative drugs, and worked hard to meet the unfinished clinical needs; in the past 25 years, we have adhered to the mission to "create excellence in pharmaceuticals, enhance innovation in China" and have marched forward in leaps and bounds.

In 2021, we will continue to fulfill our mission with great determination, remain true to our original aspiration driven by innovation, embarked on a new journey empowered by changes, and contribute to the Healthy China initiative.

We wish you and your family good health, peace and all the best!

Hansoh Pharma

January 1, 2021